Navigation Links
ERT Announces Clearance from German Federal Cartel Office

PHILADELPHIA, June 6, 2012 /PRNewswire/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERT), a global technology-driven provider of health outcomes research services to biopharmaceutical sponsors and contract research organizations, today announced that Genstar Capital LLC was informed that it received clearance from the German Federal Cartel Office to proceed with its proposed acquisition of ERT.

The transaction has been approved unanimously by the ERT Board of Directors, following a recommendation by a Special Committee of independent directors, and the ERT Board of Directors recommends that ERT stockholders approve the transaction.  At a meeting scheduled to occur on June 22, 2012, ERT's stockholders will vote on the approval of the merger agreement pursuant to which ERT has agreed to be acquired by affiliates of Genstar Capital LLC for $8.00 per share in cash.

About ERT

ERT ( is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with unrivaled processes and scientific expertise to collect, analyze, and report on clinical data to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products.  ERT is the acknowledged industry leader in centralized cardiac safety and respiratory efficacy services and also provides electronic Patient Reported Outcomes (ePRO) and outcomes assessments for multiple modalities across all phases.

About Genstar Capital

Genstar Capital ( is a leading private equity firm that has been actively investing in high quality companies for more than 20 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of operating executives and strategic advisors to transform its portfolio companies into industry-leading businesses.  Genstar has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries.

Forward-Looking Statements

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the timing of the special meeting of stockholders.  Other risks and uncertainties that may affect forward-looking statements are described in the "Risk Factors" section and elsewhere in the company's Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC) on March 2, 2012. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.  ERT's ability to complete the transaction is dependent upon stockholder approval and other customary closing conditions, not all of which are within the control of ERT or Genstar.

Additional Information and Where to Find It

ERT has filed a definitive proxy statement with the SEC. ERT'S SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT BECAUSE IT CONTAINS IMPORTANT INFORMATION. ERT's stockholders will be mailed a copy of the definitive proxy statement and a proxy voting card and may otherwise obtain, without charge, a copy of the proxy statement and other relevant documents filed with the SEC from the SEC's website at ERT's stockholders will also be able to obtain, without charge, a copy of the proxy statement and other relevant documents (when available) by going to the Investors section of ERT's corporate website,, or directing a request by mail or telephone to ERT, 1818 Market Street, Philadelphia, PA 19103-3638 – Attention Investor Relations.

ERT and its directors and officers may be deemed to be participants in the solicitation of proxies from ERT's stockholders with respect to the special meeting of stockholders that will be held to consider the merger. Information about ERT's directors and executive officers and their ownership of ERT's common stock is set forth in the definitive proxy statement. Stockholders may obtain additional information regarding the interests of ERT and its directors and executive officers in the merger, which may be different than those of the company's stockholders generally, by reading the definitive proxy statement and other relevant documents regarding the merger.

­­ERT Contact:
Keith Schneck

Genstar Contact:
Chris Tofalli
Chris Tofalli Public Relations

SOURCE eResearchTechnology, Inc. (ERT)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
2. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
3. SIRO Clinpharm Announces a Fabulous Date With the Dueling Pianos
4. Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. The Galien Foundation Announces New "Best Medical Technology" Award Category for 2012 Prix Galien USA Awards Program
7. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
8. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
9. Regeneron Announces June 2012 Investor Conference Presentations
10. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
11. Accelrys Announces Software Licensing Agreement with Gulf Coast Consortia
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... Dental Association meeting in Washington D.C. revolved around the fact that proper dental care, ... The talk stressed the link between periodontal disease (more commonly referred to as gum ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the ... Table 1-1 ). More than 3.7 billion people under the age of 50 ... (HSV-1), according to WHO's first global estimates of HSV-1 infection . , "The data ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
Breaking Medicine News(10 mins):